{"id":"W2567730437","doi":"10.1016/j.jtho.2016.11.355","title":"OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nintedanib; Medicine; Placebo; Pemetrexed; Internal medicine; Bevacizumab; Clinical endpoint; Adverse effect; Neutropenia; Oncology; Pazopanib; Cisplatin; Gastroenterology; Urology; Surgery; Chemotherapy; Randomized controlled trial; Pathology; Cancer; Idiopathic pulmonary fibrosis; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001032797,0.001185881,0.002460086,0.0003056853,0.0003021346,0.001159742,0.0006598079,0.0008201759,0.004117522],"category_scores_gemma":[0.0009806103,0.0004333156,0.001687074,0.0003382668,0.0007454047,0.001050287,0.000312184,0.002897164,0.0008262545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006418154,"about_ca_system_score_gemma":0.0007706643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008961436,"about_ca_topic_score_gemma":0.002754808,"domain_scores_codex":[0.9997124,0.0001401931,0.00001675694,0.00005277889,0.00002014756,0.00005762723],"domain_scores_gemma":[0.9996171,0.00008361085,0.0000764717,0.0000298592,0.00002288812,0.0001700279],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8852693,0.007222972,0.002068421,0.002101095,0.003169217,0.0001208755,0.0001087196,0.001398528,0.009545534,0.0002808616,0.003400392,0.08531409],"study_design_scores_gemma":[0.8747146,0.1111563,0.007953121,0.0001368826,0.001398968,0.0001364462,0.00007057517,0.0007577083,0.0008209689,0.0002706576,0.002551738,0.00003207349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765818,0.01561127,0.0004789871,0.001287867,0.0006172103,0.0009168384,0.001111884,0.0001657996,0.003228412],"genre_scores_gemma":[0.9865021,0.006341636,0.0006722148,0.001089943,0.0002814891,0.0007669755,0.001409733,0.00002713744,0.002908678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004117522,"threshold_uncertainty_score":0.01377445,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01993698530407767,"score_gpt":0.3833179797904933,"score_spread":0.3633809944864156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}